The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus
Background: COVID-19 is responsible for the latest pandemic. Dipeptidyl peptidase-4 (DPP-4) is one of the cellular receptors of interest for coronavirus. The aim of this study was to assess the roles of DPP-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus. Ma...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Journal of Research in Medical Sciences |
| Subjects: | |
| Online Access: | http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2022;volume=27;issue=1;spage=62;epage=62;aulast=Sadidi |
| _version_ | 1818054710761881600 |
|---|---|
| author | Mohammad Sadidi Ahad Zare Mehrdad Nasrollahzadehsabet Farzaneh Dastan Ali Mosadegh Khah Milad Jafari Asheyani |
| author_facet | Mohammad Sadidi Ahad Zare Mehrdad Nasrollahzadehsabet Farzaneh Dastan Ali Mosadegh Khah Milad Jafari Asheyani |
| author_sort | Mohammad Sadidi |
| collection | DOAJ |
| description | Background: COVID-19 is responsible for the latest pandemic. Dipeptidyl peptidase-4 (DPP-4) is one of the cellular receptors of interest for coronavirus. The aim of this study was to assess the roles of DPP-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus. Materials and Methods: A retrospective cohort study was performed in 2020 in military medical centers affiliated to AJA University of Medical Sciences in Tehran on 220 patients with type 2 diabetes mellitus who were admitted in medical centers with COVID-19 infection. We collected demographic data of patients including age, gender, drug history, usage of DPP-4 inhibitors, clinical presentations at the time of the first visit, and the disease outcome including hospitalization duration and need for respiratory assist. Results: The study population consisted of 133 males (60.5%) and 87 females (39.5%), with a mean age of 66.13 ± 12.3 years. Forty-four patients (20%) consumed DPP-4 inhibitors (sitagliptin and linagliptin). Patients who were treated with DPP-4 inhibitors required less oxygen (O2) therapies compared to other cases (76.7% vs. 88.6%, P = 0.04). Patients who were treated with DPP-4 inhibitors had significantly lower hospitalization duration compared to other cases (6.57 ± 2.3 days vs. 8.03 ± 4.4 days, respectively, P = 0.01). There were no significant differences between the two groups of patients regarding survival rates (P = 0.55). Age was a predictive factor for survival (odds ratio, 1.13; 95% confidence interval, 1.04–1.23; P = 0.004). Conclusion: DPP-4 inhibitors could significantly decrease hospitalization days in patients with type 2 diabetes mellitus who were hospitalized for COVID-19. However, DPP-4 inhibitor usage showed no statistically significant impact on survival. Age was the important prognostic factor. |
| first_indexed | 2024-12-10T12:01:23Z |
| format | Article |
| id | doaj.art-0871b030513a4021b29736e2ecca247b |
| institution | Directory Open Access Journal |
| issn | 1735-1995 1735-7136 |
| language | English |
| last_indexed | 2024-12-10T12:01:23Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Research in Medical Sciences |
| spelling | doaj.art-0871b030513a4021b29736e2ecca247b2022-12-22T01:49:36ZengWolters Kluwer Medknow PublicationsJournal of Research in Medical Sciences1735-19951735-71362022-01-01271626210.4103/jrms.jrms_71_22The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitusMohammad SadidiAhad ZareMehrdad NasrollahzadehsabetFarzaneh DastanAli Mosadegh KhahMilad Jafari AsheyaniBackground: COVID-19 is responsible for the latest pandemic. Dipeptidyl peptidase-4 (DPP-4) is one of the cellular receptors of interest for coronavirus. The aim of this study was to assess the roles of DPP-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus. Materials and Methods: A retrospective cohort study was performed in 2020 in military medical centers affiliated to AJA University of Medical Sciences in Tehran on 220 patients with type 2 diabetes mellitus who were admitted in medical centers with COVID-19 infection. We collected demographic data of patients including age, gender, drug history, usage of DPP-4 inhibitors, clinical presentations at the time of the first visit, and the disease outcome including hospitalization duration and need for respiratory assist. Results: The study population consisted of 133 males (60.5%) and 87 females (39.5%), with a mean age of 66.13 ± 12.3 years. Forty-four patients (20%) consumed DPP-4 inhibitors (sitagliptin and linagliptin). Patients who were treated with DPP-4 inhibitors required less oxygen (O2) therapies compared to other cases (76.7% vs. 88.6%, P = 0.04). Patients who were treated with DPP-4 inhibitors had significantly lower hospitalization duration compared to other cases (6.57 ± 2.3 days vs. 8.03 ± 4.4 days, respectively, P = 0.01). There were no significant differences between the two groups of patients regarding survival rates (P = 0.55). Age was a predictive factor for survival (odds ratio, 1.13; 95% confidence interval, 1.04–1.23; P = 0.004). Conclusion: DPP-4 inhibitors could significantly decrease hospitalization days in patients with type 2 diabetes mellitus who were hospitalized for COVID-19. However, DPP-4 inhibitor usage showed no statistically significant impact on survival. Age was the important prognostic factor.http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2022;volume=27;issue=1;spage=62;epage=62;aulast=Sadidicovid-19dipeptidyl peptidase iv inhibitorsprognosis |
| spellingShingle | Mohammad Sadidi Ahad Zare Mehrdad Nasrollahzadehsabet Farzaneh Dastan Ali Mosadegh Khah Milad Jafari Asheyani The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus Journal of Research in Medical Sciences covid-19 dipeptidyl peptidase iv inhibitors prognosis |
| title | The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus |
| title_full | The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus |
| title_fullStr | The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus |
| title_full_unstemmed | The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus |
| title_short | The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus |
| title_sort | roles of dipeptidyl peptidase 4 inhibitors in prognosis of covid 19 infection in patients with type 2 diabetes mellitus |
| topic | covid-19 dipeptidyl peptidase iv inhibitors prognosis |
| url | http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2022;volume=27;issue=1;spage=62;epage=62;aulast=Sadidi |
| work_keys_str_mv | AT mohammadsadidi therolesofdipeptidylpeptidase4inhibitorsinprognosisofcovid19infectioninpatientswithtype2diabetesmellitus AT ahadzare therolesofdipeptidylpeptidase4inhibitorsinprognosisofcovid19infectioninpatientswithtype2diabetesmellitus AT mehrdadnasrollahzadehsabet therolesofdipeptidylpeptidase4inhibitorsinprognosisofcovid19infectioninpatientswithtype2diabetesmellitus AT farzanehdastan therolesofdipeptidylpeptidase4inhibitorsinprognosisofcovid19infectioninpatientswithtype2diabetesmellitus AT alimosadeghkhah therolesofdipeptidylpeptidase4inhibitorsinprognosisofcovid19infectioninpatientswithtype2diabetesmellitus AT miladjafariasheyani therolesofdipeptidylpeptidase4inhibitorsinprognosisofcovid19infectioninpatientswithtype2diabetesmellitus AT mohammadsadidi rolesofdipeptidylpeptidase4inhibitorsinprognosisofcovid19infectioninpatientswithtype2diabetesmellitus AT ahadzare rolesofdipeptidylpeptidase4inhibitorsinprognosisofcovid19infectioninpatientswithtype2diabetesmellitus AT mehrdadnasrollahzadehsabet rolesofdipeptidylpeptidase4inhibitorsinprognosisofcovid19infectioninpatientswithtype2diabetesmellitus AT farzanehdastan rolesofdipeptidylpeptidase4inhibitorsinprognosisofcovid19infectioninpatientswithtype2diabetesmellitus AT alimosadeghkhah rolesofdipeptidylpeptidase4inhibitorsinprognosisofcovid19infectioninpatientswithtype2diabetesmellitus AT miladjafariasheyani rolesofdipeptidylpeptidase4inhibitorsinprognosisofcovid19infectioninpatientswithtype2diabetesmellitus |